|
Design and rationale of a phase 1 dose-escalation study of AMG 193, a methylthioadenosine (MTA)-cooperative PRMT5 inhibitor, in patients with advanced methylthioadenosine phosphorylase (MTAP)-null solid tumors. |
| |
Miguel Angel Villalona-Calero |
Stock and Other Ownership Interests - Moderna Therapeutics |
Consulting or Advisory Role - Lilly |
|
Research Funding - Altor BioScience (Inst); Bristol-Myers Squibb (Inst); Guardant Health (Inst); Merck (Inst); Novocure (Inst); Tolero Pharmaceuticals (Inst) |
| |
|
Honoraria - Texas Society of Clinical Oncology (TxSCO) |
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb (I); Daiichi Sankyo, Inc.; Genentech/Roche (I); Gilead Sciences; HalioDx; Ionova; Merck; MERCK (I); Novartis; Seagen; Silverback Therapeutics |
Research Funding - Abbvie (Inst); Alpine Immune Sciences (Inst); Amgen (Inst); Arcus Ventures (Inst); Astellas Pharma (Inst); Bolt Biotherapeutics (Inst); Corvus Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Daiichi-Sankyo (Inst); Exelixis (Inst); Five Prime Therapeutics (Inst); Fochon Pharmaceuticals (Inst); Forty Seven (Inst); Gilead Sciences (Inst); Infinity Pharmaceuticals (Inst); Institut de Recherches Internationales Servier (I.R.I.S) (Inst); Ionova (Inst); Ionova (Inst); Klus Pharma (Inst); KSQ Theraeutics (Inst); Lilly (Inst); Livzon (Inst); Loxo@Lilly (Inst); Merck (Inst); Nektar (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Pionyr (Inst); Plexxikon (Inst); Sanofi (Inst); Seagen (Inst); Seagen (Inst); Surface Oncology (Inst); Symphogen (Inst); Syndax (Inst); Tesaro (Inst); Upsher-Smith (Inst); Vigeo Therapeutics (Inst) |
| |
|
Consulting or Advisory Role - Bayer; Daiichi Sankyo/Lilly; Deciphera; Ipsen; Karyopharm Therapeutics; PEEL Therapeutics; TRACON Pharma; UpToDate |
|
Research Funding - Amgen (Inst); Astex Pharmaceuticals (Inst); Bayer (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); C4 Therapeutics (Inst); Daiichi (Inst); Exelixis (Inst); InhibRx (Inst); PEEL Therapeutics (Inst); Presage Biosciences (Inst); Rain Therapeutics (Inst); Regeneron (Inst); Regeneron (Inst); SARC: Sarcoma Alliance for Research though Collaboration (Inst); SpringWorks Therapeutics (Inst); SynOx (Inst); TRACON Pharma (Inst) |
Patents, Royalties, Other Intellectual Property - Uptodate: I write and edit chapters for their online text book. |
Travel, Accommodations, Expenses - SpringWorks Therapeutics; TRACON Pharma |
| |
|
|
|
| |
|
Stock and Other Ownership Interests - Bessor Pharma; Moleculin Biotech |
Honoraria - AstraZeneca; Fujifilm; Pancreatic Cancer Action Network; Sun Pharma |
Consulting or Advisory Role - AstraZeneca; Bessor Pharma; Fujifilm; Moleculin Biotech; Pancreatic Cancer Action network; Sun Biopharma |
Research Funding - Pfizer (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
| |
|
Honoraria - American Academic Health System; American Society of Clinical Oncology; Creative Educational Concepts; DAVA Oncology; Medscape; OncLive/MJH Life Sciences; Total Health Conferencing |
Consulting or Advisory Role - AstraZeneca; Bayer; Boehringer Ingelheim; BostonGene; Catalyst Pharmaceuticals; Genentech; Janssen; Novocure; Pfizer; Sanofi; Syros Pharmaceuticals; Xcovery |
Research Funding - Array BioPharma (Inst); Calithera Biosciences (Inst); Genentech (Inst); Novartis (Inst); Pfizer (Inst); Vivace Therapeutics (Inst) |
Travel, Accommodations, Expenses - Array BioPharma; Pfizer |
| |
|
No Relationships to Disclose |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Daiichi Sankyo; Lilly; Novartis; Novartis; Roche |
Consulting or Advisory Role - Abbvie; Blueprint Medicines; Boehringer Ingelheim; Daiichi Sankyo; Novartis; PharmaEngine |
Travel, Accommodations, Expenses - BeiGene; Daiichi Sankyo; Daiichi Sankyo; Lilly; Novartis |
| |
|
Honoraria - AstraZeneca/MedImmune; Bristol-Myers Squibb Japan; Chugai Pharma; Lilly Japan; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical |
Consulting or Advisory Role - AstraZeneca; Chiome Bioscience; Daiichi Sankyo; MSD; Ono Pharmaceutical; Otsuka |
Research Funding - Amgen (Inst); Anheart Therapeutics (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Lilly Japan (Inst) |
| |
|
No Relationships to Disclose |
| |
|
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Adlai Nortye (Inst); Aduro Biotech (Inst); Agios (Inst); Amgen (Inst); arGEN-X BVBA (Inst); Arno Therapeutics (Inst); Astex Pharmaceuticals (Inst); AstraZeneca (Inst); AVEO (Inst); Basilea (Inst); Bayer (Inst); BBB Technologies (Inst); BeiGene (Inst); Bicycle Therapeutics (Inst); BioAlliance Pharma (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Boston Pharmaceuticals (Inst); Bristol Myers Squibb Foundation (Inst); Celgene (Inst); Chibret (Inst); Chugai Pharma (Inst); Cullinan Oncology (Inst); CureVac (Inst); Daiichi Sankyo (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); Faron Pharmaceuticals (Inst); Forma Therapeutics (Inst); GamaMabs Pharma (Inst); Genentech (Inst); GlaxoSmithKline (Inst); H3 Biomedicine (Inst); Imcheck Therapeutics (Inst); Innate Pharma (Inst); Institut de Recherches Internationales Servier (Inst); ITeos Therapeutics (Inst); Janssen Research & Development (Inst); Janssen-Cilag (Inst); Kura Oncology (Inst); Kyowa Kirin (Inst); Lilly (Inst); Lilly (Inst); Loxo (Inst); Lytix Biopharma (Inst); MedImmune (Inst); Menarini (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Molecular Partners (Inst); Nanobiotix (Inst); Nektar (Inst); Novartis Pharmaceuticals UK Ltd. (Inst); Octimet (Inst); Oncoethix (Inst); Oncopeptides (Inst); Onyx (Inst); Orion (Inst); Oryzon Genomics (Inst); ose pharma (Inst); Pfizer (Inst); Pharma Marathi (Inst); Pierre Fabre (Inst); Pierre Fabre (Inst); Plexxikon (Inst); Roche (Inst); Roche Pharma AG (Inst); Sanofi Aventis GmbH (Inst); Seagen (Inst); Sotio (Inst); Syros Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Tesaro (Inst); Turning Point Therapeutics (Inst); Xencor (Inst) |
| |
|
Honoraria - Bristol-Myers Squibb; Janssen; Novartis |
Consulting or Advisory Role - GEMoaB; Janssen |
Travel, Accommodations, Expenses - Janssen; Novartis; Roche |
| |
|
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bristol Myers Squibb Foundation; Lilly; MSD Oncology; Novartis; Pfizer; Roche |
Speakers' Bureau - AstraZeneca/MedImmune; Lilly |
Travel, Accommodations, Expenses - Roche; Takeda |
| |
|
Honoraria - Amgen; Bayer; Roche; Sanofi |
| |
|
No Relationships to Disclose |
| |
|
Honoraria - Amgen; AstraZeneca; Genentech/Roche |
Consulting or Advisory Role - Amgen; AstraZeneca/MedImmune; Genentech/Roche |
Research Funding - AstraZeneca; Genentech/Roche |
| |
|
|
Stock and Other Ownership Interests - Amgen |
| |
|
|
Stock and Other Ownership Interests - Amgen |
| |
|
Consulting or Advisory Role - Ellipses Pharma; iOnctura; Kelun Pharmaceuticals/Klus Pharma; Molecular Partners; Peptomyc |
Research Funding - AADi (Inst); Amgen (Inst); Bayer (Inst); Bicycle Therapeutics (Inst); BioAtla (Inst); BioMed Valley Discoveries (Inst); Black Diamond Therapeutics (Inst); Blueprint Medicines (Inst); Cellestia Biotech (Inst); Curis (Inst); CytomX Therapeutics (Inst); Deciphera (Inst); Fore Biotherapeutics (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Hummingbird (Inst); Hutchison MediPharma (Inst); IDEAYA Biosciences (Inst); Kelun (Inst); Linnaeus Therapeutics (Inst); Loxo (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Nuvation Bio (Inst); Pfizer (Inst); Roche (Inst); Spectrum Pharmaceuticals (Inst); Symphogen (Inst); Taiho Pharmaceutical (Inst); Takeda/Millennium (Inst); Tango Therapeutics (Inst); Vall d'Hebron Institute of Oncology/Cancer Core Europe (Inst); Yingli Pharma (Inst) |
Travel, Accommodations, Expenses - ESMO |
Other Relationship - Boxer Capital; Chinese University of Hong Kong; Tang Advisors; Vall d'Hebron Institute of Oncology/Ministerio De Empleo Y Seguridad Social |